DCM
MRTX

Delpha Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Delpha Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,294
Closed -$24K – 1333
2017
Q4 		$24K Buy
+1,294
New +$20.1K 0.03% 692

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Delpha Capital Management's MRTX Position: Q1 2018 in Review

Delpha Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2018, closing a stake of 1,294 shares — an estimated $24K sold.

Delpha Capital Management first reported a position in MRTX in Q4 2017 and held it in 1 quarter. The position peaked at $24K in Q4 2017. 81 funds tracked by Wall St. Rank hold MRTX as of Q1 2018.

  • Delpha Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 1,294 Mirati Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $24K.
  • Delpha Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $24K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.